In last trading session, ITeos Therapeutics Inc (NASDAQ:ITOS) saw 0.34 million shares changing hands with its beta currently measuring 1.35. Company’s recent per share price level of $7.35 trading at -$0.11 or -1.47% at ring of the bell on the day assigns it a market valuation of $280.73M. That closing price of ITOS’s stock is at a discount of -155.1% from its 52-week high price of $18.75 and is indicating a premium of 34.69% from its 52-week low price of $4.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.63 million shares which gives us an average trading volume of 364.32K if we extend that period to 3-months.

For ITeos Therapeutics Inc (ITOS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.9 in the current quarter.

ITeos Therapeutics Inc (NASDAQ:ITOS) trade information

Upright in the red during last session for losing -1.47%, in the last five days ITOS remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $7.35 price level, adding 2.78% to its value on the day. ITeos Therapeutics Inc’s shares saw a change of -4.30% in year-to-date performance and have moved 12.90% in past 5-day. ITeos Therapeutics Inc (NASDAQ:ITOS) showed a performance of 13.08% in past 30-days. Number of shares sold short was 1.83 million shares which calculate 4.77 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 56.76% to its current value. Analysts have been projecting 17 as a low price target for the stock while placing it at a high target of 17. It follows that stock’s current price would drop -131.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of -131.29% for stock’s current value.

ITeos Therapeutics Inc (ITOS) estimates and forecasts

This year revenue growth is estimated to fall -78.63% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.8M for the same. And 5 analysts are in estimates of company making revenue of 1.8M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -34.39% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -21.27% while estimates for its earnings growth in next 5 years are of -5.39%.

ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders

Insiders are in possession of 1.13% of company’s total shares while institution are holding 90.87 percent of that, with stock having share float percentage of 91.91%. Investors also watch the number of corporate investors in a company very closely, which is 90.87% institutions for ITeos Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ITOS for having 3.73 million shares of worth $55.37 million. And as of 2024-06-30, it was holding 9.3983 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 3.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8598 of outstanding shares, having a total worth of $52.2 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 855.64 shares of worth $6.29 million or 2.24% of the total outstanding shares. The later fund manager was in possession of 719.67 shares on Mar 31, 2025 , making its stake of worth around $5.29 million in the company or a holder of 1.88% of company’s stock.